Carregant...
Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
BACKGROUND: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody...
Guardat en:
| Publicat a: | Iran Biomed J |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Pasteur Institute
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5889503/ https://ncbi.nlm.nih.gov/pubmed/28992681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/ibj.22.3.180 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|